Effects of diet-induced metabolic syndrome on cardiac function and angiogenesis in response to the sodium-glucose cotransporter-2 inhibitor canagliflozin

J Thorac Cardiovasc Surg. 2024 Nov;168(5):e183-e199. doi: 10.1016/j.jtcvs.2024.06.004. Epub 2024 Jun 13.

Abstract

Introduction: Sodium-glucose cotransporter-2 inhibitors are antidiabetic medications that have been shown to decrease cardiovascular events and heart failure-related mortality in clinical studies. We attempt to examine the complex interplay between metabolic syndrome and the sodium-glucose cotransporter-2 inhibitor canagliflozin (CAN) in a clinically relevant model of chronic myocardial ischemia.

Methods: Twenty-one Yorkshire swine were fed a high-fat diet starting at 6 weeks of age to induce metabolic syndrome. At 11 weeks, all underwent placement of an ameroid constrictor around the left circumflex coronary artery to induce chronic myocardial ischemia. After 2 weeks, swine received either control (CON) (n = 11) or CAN 300 mg by mouth daily (n = 10) for 5 weeks, whereupon all underwent terminal harvest.

Results: There was a significant increase in cardiac output and heart rate with a decrease in pulse pressure in the CAN group compared with CON (all P values < .05). The CAN group had a significant increase in capillary density (P = .02). There was no change in myocardial perfusion or arteriolar density. CAN induced a significant increase in markers of angiogenesis, including Phospho-endothelial nitric oxide synthase, Endothelial nitric oxide synthase, vascular endothelial growth factor receptor-1, heat shock protein 70, and extracellular signal-regulated kinases (all P values < .05), plausibly resulting in capillary angiogenesis.

Conclusions: CAN treatment leads to a significant increase in capillary density and augmented cardiac function in a swine model of chronic myocardial ischemia in the setting of metabolic syndrome. This work further elucidates the mechanism of sodium-glucose cotransporter-2 inhibitors in patients with cardiac disease; however, more studies are needed to determine if this increase in capillary density plays a role in the improvements seen in clinical studies.

Keywords: ameroid constrictor; angiogenesis; canagliflozin; chronic myocardial ischemia; metabolic syndrome; sodium-glucose cotransporter-2 inhibitor.

MeSH terms

  • Angiogenesis
  • Animals
  • Canagliflozin* / pharmacology
  • Diet, High-Fat*
  • Disease Models, Animal*
  • Metabolic Syndrome* / chemically induced
  • Metabolic Syndrome* / physiopathology
  • Myocardial Ischemia* / chemically induced
  • Myocardial Ischemia* / physiopathology
  • Neovascularization, Physiologic* / drug effects
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sus scrofa
  • Swine

Substances

  • Canagliflozin
  • Sodium-Glucose Transporter 2 Inhibitors